This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia

Article date: July 2019

By: Rihwa Choi, Insuk Sohn, Min‐Ji Kim, Hye In Woo, Ji Won Lee, Youngeun Ma, Eun Sang Yi, Hong Hoe Koo, Soo‐Youn Lee in Volume 85, Issue 7, pages 1585-1597

Aims

We aimed to investigate the impact of various genetic polymorphisms affecting thiopurine metabolism pathways and toxicity in paediatric acute lymphoblastic leukaemia patients for the first time in Korea.

Methods

From May 2006 to September 2016, 139 paediatric acute lymphoblastic leukaemia patients treated with combination chemotherapy including 6‐mercaptopurine were included in the study. One hundred and twenty‐three variants in 43 genes, including TMPT and NUDT15, were screened using targeted genotyping, such as a MassARRAY system, direct sequencing and polymerase chain reaction‐restriction fragment length polymorphism methods. Among the polymorphisms screened, 103 polymorphisms of 43 genes were included for further analyses.

Results

The genetic polymorphisms in the ABCC4, AHCY, ATIC, FAM8A6P, GART, GNG2, GSTA1, MTHFD1, MTHFR, NUDT15, PACSIN2, TYMS and XDH genes, and an intronic polymorphism between HIVEP2 and AIG1, and TPMT genotype were associated with thiopurine metabolism (P < 0.05). Genetic polymorphisms in the ABCC4, ADK, ATIC, GART, GMPS, GSTP1, IMPDH1, ITPA, KCNMA1, MOCOS, MTRR, NUDT15, SLC19A1, SLC28A3, SLC29A1, SLCO1B1, TYMP and XDH genes were associated with thiopurine‐related toxicities; neutropenia, hepatotoxicity and treatment interruption (P < 0.05).

Conclusions

Findings of this study may provide basic knowledge for personalized medicine for thiopurinxe treatment in paediatric acute lymphoblastic leukaemia patients.

DOI: 10.1111/bcp.13943

View this article